Background:

Non-infective uveitis is a major cause of vision loss in adults, characterized by inflammation in the eye’s uveal tract, which includes the iris, ciliary body, and choroid. If untreated, it can lead to severe complications like cataracts, glaucoma, macular edema, and permanent vision loss. Traditional treatments, including corticosteroids and immunosuppressive agents, are effective but often come with significant side effects and are not always well-tolerated by patients.

Adalimumab, a biologic agent that targets tumor necrosis factor (TNF)-alpha, has shown promise in the treatment of inflammatory conditions, including non-infective uveitis. While previous studies have demonstrated the efficacy of adalimumab in managing non-infective uveitis, there is limited data on its long-term effects and sustained benefits, especially in the Indian population.

Purpose of the Trial:

The primary objective of this study is to evaluate the effectiveness of adalimumab in the management of non-infective uveitis in adults, with a focus on its ability to control ocular inflammation and maintain remission over a period of 1 year. The trial aims to assess how well adalimumab controls uveitis inflammation, its impact on visual acuity, and its safety profile when used as a long-term treatment option.

This study will contribute to better understanding the role of adalimumab in managing chronic uveitis and could potentially offer a more effective and well-tolerated alternative to existing treatments. Additionally, the results may help establish guidelines for its use in clinical practice, particularly in cases of uveitis that are resistant to conventional therapies.